IGC Pharma (IGC) Total Current Liabilities (2011 - 2026)

IGC Pharma (IGC) has 16 years of Total Current Liabilities data on file, last reported at $2.9 million in Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $2.9 million, up 27.29% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.9 million (up 27.29% YoY), and the FY2026 annual result was $2.9 million, up 27.29% from the prior year.
• Total Current Liabilities advanced to $2.9 million in Q1 2026 per IGC's latest filing, from $2.2 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $2.9 million in Q1 2026 and troughed at $1.4 million in Q4 2022.
• A 5-year average of $2.1 million and a median of $2.1 million in 2023 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2023 and 2025: Total Current Liabilities surged 52.39% in 2023, then sank 45.97% in 2025.
• A 5-year view of Total Current Liabilities shows it stood at $1.4 million in 2022, then surged by 42.77% to $1.9 million in 2023, then jumped by 37.24% to $2.7 million in 2024, then fell by 18.86% to $2.2 million in 2025, then jumped by 33.26% to $2.9 million in 2026.
• Business Quant data shows IGC's Total Current Liabilities at $2.9 million in Q1 2026, $2.2 million in Q4 2025, and $1.5 million in Q3 2025.